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Following infection with lymphocytic choriomeningitis virus (LCMV), normal adult mice generate virus-
specific, major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes (CTL) which clear
the virus after intraperitoneal infection or cause death following intracranial (i.c.) infection. We have inves-
tigated the response of b2-microglobulin-deficient (b2m
2) mice of the H-2d haplotype (KOD mice) to LCMV
infection. Unlike H-2b b2m
2 mice, which generate CD41 MHC class II-restricted CTL in response to LCMV,
KOD mice generate high levels of CD81 MHC class I-restricted, virus-specific CTL. These CTL are specific for
the LCMV nucleoprotein epitope (residues 118 to 126) in association with the Ld class I molecule, analogous
to the CTL response in wild-type mice. KOD mice are also susceptible to lethal LCM disease, with 75 to 80%
of the mice dying 7 to 9 days following i.c. infection with virus. Similar to results with normal mice, lethal LCM
disease in KOD mice is prevented by in vivo depletion of CD81 T cells prior to i.c. infection. In contrast to
wild-type mice, however, KOD mice cannot control LCMV and become persistently infected. Overall, these
results demonstrate that b2m is not an absolute requirement for presentation of endogenous antigen on L
d or
for induction of virus-specific Ld-restricted CTL in vivo.
Major histocompatibility complex (MHC) class I molecules
bind peptides of generally 8 to 10 amino acids in length which
are derived from endogenously synthesized proteins (28, 33).
These peptides are translocated from the cytosol into the en-
doplasmic reticulum via the heterodimeric transporter associ-
ated with antigen processing (TAP). In the endoplasmic retic-
ulum, antigenic peptide binds to the MHC class I heavy-chain
and the noncovalently associated light-chain b2-microglobulin
(b2m) (15). The resulting trimolecular complex transits to the
cell surface via the secretory pathway, where it can be recog-
nized by CD81 cytotoxic T lymphocytes (CTL).
Experiments using b2m-deficient (b2m
2) mice (17, 38) have
conclusively demonstrated the crucial role of b2m in antigen
presentation to CD81 T cells. b2m
2 mice are deficient in cell
surface expression of correctly conformed MHC class I mole-
cules, and as a consequence, they are defective in thymic se-
lection of CD81 T cells. These mice, therefore, have negligible
numbers of peripheral CD81 cells (17, 38), and unlike normal
mice, b2m
2 mice typically fail to generate MHC class I-re-
stricted CTL in response to virus infection. Instead, b2m
2 mice
generate CD41 MHC class II-restricted CTL following infec-
tion with Sendai virus (16) or with lymphocytic choriomenin-
gitis virus (LCMV) (11, 20, 23, 27). In contrast to what occurs
after viral infection, injection of b2m
2 mice with allogeneic
b2m
1 cells results in the expansion of highly cytolytic CD81 T
cells (3, 4, 18, 26, 31). This demonstrates that, if given a suffi-
ciently potent stimulus, b2m
2 mice can elaborate functional
CD81 CTL. It has also been shown that b2m
2 cells express low
levels of correctly conformed MHC class I molecules on their
surfaces (1, 6) and furthermore that the class I molecules
expressed on b2m
2 cells can present endogenous antigen to
CD81 T cells from normal mice (14, 19, 26, 39). These findings
suggest that the presentation of certain endogenously derived
antigens on “free” (non-b2m-associated) MHC class I heavy
chains might result in induction of CD81 CTL in b2m
2 mice.
To address this possibility, we have investigated the antiviral
CTL responses of different strains of b2m
2 mice. In this report
we demonstrate the induction of high levels of CD81, MHC




Virus. The Armstrong-3 strain of LCMV was originally obtained from J. L.
Whitton (The Scripps Research Institute, La Jolla, Calif.) and was propagated in
BHK-21 cells (American Type Culture Collection, Rockville, Md.). Infectious
supernatants were titrated on Vero cell monolayers as previously described (37).
Mice. b2m2 mice were crossed with BALB/c mice to generate H-2d b2m2 mice
(KOD mice). These mice were obtained from F. Wells (National Cancer Insti-
tute, Frederick, Md.) (34) and were maintained in specific-pathogen-free,
AAALAC-accredited facilities at the University of North Carolina, Chapel
Hill, and at Loyola University Medical Center, Maywood, Ill. C57BL/6J (B6;
H-2b), C57BL/6J-B2mtm1UNC (B6.b2m2), AKR/J (H-2k), AKR/J-B2mtm1UNC
(AKR.b2m2), and BALB/cJ mice were obtained from The Jackson Laboratory
(Bar Harbor, Maine). Male and female mice were used at 7 to 14 weeks of age.
Mice were infected via the intraperitoneal (i.p.) route with either 2 3 102 or 2 3
104 PFU of LCMV in a volume of 0.4 ml. Spleens were removed from mice either
20 days or 120 days following i.p. infection with LCMV for determination of virus
titers. The spleens were homogenized, and virus titers in the supernatants were
measured by plaque assay on Vero cell monolayers as previously described (37).
For intracranial (i.c.) infections, mice were anesthetized with Metofane (Pitman-
Moore Inc., Mundelein, Ill.) and injected i.c. with either 2 3 103 or 2 3 105 PFU
of LCMV in a volume of 20 ml. Following i.c. infection, mice were monitored
daily for morbidity and mortality.
Cell lines. C1R cells transfected with H-2Ld (C1R-Ld) and the control cell line
C1R-neo were obtained from P. Cresswell (Yale University School of Medicine,
New Haven, Conn.) (10) and were maintained in D-10 (Dulbecco’s modified
Eagle’s medium containing 10% fetal calf serum [FCS] and 50 mM 2-mercapto-
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ethanol), supplemented with 1 mg of G418 (Gibco BRL, Grand Island, N.Y.) per
ml. The C1R-Ld/NP and the C1R-neo/NP cell lines were generated as follows.
The pARM NP-A construct containing the LCMV Armstrong-3 nucleoprotein
(NP) gene was obtained from J. L. Whitton (35). The NotI-SphI restriction
fragment encoding NP was excised from pARM NP-A and was inserted into the
BamHI site of the episomal vector p8901 (2) by blunt-end ligation. The resulting
p8901-NP construct was transfected into C1R-Ld and C1R-neo cells by electro-
poration with a Bio-Rad Gene Pulser. Transfected cells were selected with D-10
supplemented with 1 mg of G418 per ml and 2 mg of hygromycin B (Calbiochem,
San Diego, Calif.) per ml. NP expression in these C1R-Ld/NP and C1R-neo/NP
transfectants was confirmed by immunocytochemistry with an NP-specific mono-
clonal antibody generously provided by M. J. Buchmeier (25). The C1R-Ld cell
line was also transfected with the p8901 vector as a control (C1R-Ld/p8901).
The fibroblastoid MC57 (H-2b) and L cell (H-2k) lines have been previously
described (23). These cells were cultured in RPMI 1640 medium supplemented
with 10% FCS and 50 mM 2-mercaptoethanol.
Peptide synthesis. The immunodominant LCMV epitope recognized by CTL
from H-2d mice has been mapped to residues 118 to 126 of the viral NP (30, 36).
The peptide sequence corresponding to this region (RPQASGVYM) was syn-
thesized by the University of North Carolina Peptide Synthesis Facility with a
Bioresearch 9500 automated synthesizer and was purified by high-performance
liquid chromatography before use.
Cytotoxicity assays. Spleens were removed from mice 8 days following i.p.
infection with LCMV. The spleens were disrupted and erythrocytes were re-
moved by osmotic lysis. These effector cells were assayed for LCMV-specific
CTL activity by standard 51Cr-release assays as previously described (37). The
target cell lines used in these assays were the C1R-neo/p8901, C1R-Ld/p8901,
and C1R-Ld/NP cell lines described above, as well as LCMV-infected and mock-
infected MC57 and L cell lines. Infection of MC57 cells and L cells with LCMV
was performed exactly as described previously (23, 26). In some experiments
C1R-neo/p8901 and C1R-Ld/p8901 cells were incubated with 2 mM NP residue
118 to 126 peptide at 37°C for 1 h after being loaded with 51Cr. Unbound peptide
was removed by washing the cells with medium containing 5% FCS, and these
peptide-pulsed cells were then used as targets in 51Cr-release assays. Effector
cells were incubated with the target cells for 5 h at 37°C in 5% CO2. Supernatants
were harvested with a Skatron Instruments (Sterling, Va.) harvesting system, and
the amount of 51Cr released was quantified with a g-counter (Packard, Sterling,
Va.). All assays were performed in triplicate, and the percent specific lysis was
determined by the formula percent specific lysis 5 [(cpm released in the pres-
ence of effectors 2 spontaneous release)/(total release 2 spontaneous release)]
3 100, where total release is the counts per minute (cpm) released from target
cells by addition of 5% (vol/vol) Triton X-100 (final concentration) and sponta-
neous release is the counts per minute released from target cells in the absence
of effectors.
Depletion of T-cell subsets. In vitro T-cell-depletion experiments were per-
formed as previously described (37) except that the antibodies used in this study
were 174.2 (anti-murine CD4) (7) and 31M-6 (anti-murine CD8) (29). LCMV-
specific CTL activity of effector cells depleted of specific T-cell subsets was
measured by standard 51Cr-release assays as described above. Depletion of T
cells in vivo was done with the antibodies GK1.5 (CD4) and 53-6.72 (CD8) as
previously described (27).
Flow cytometry. Effector cells were prepared from the spleens of mice 8 days
following i.p. infection with 2 3 104 PFU of LCMV as described above. Cells
were resuspended at 107 cells/ml in RPMI 1640 containing 5% FCS. Aliquots of
the cell suspension (5 3 105 cells) were taken and incubated with the monoclonal
antibody 2.4G2 (32) at a concentration of 0.4 mg/106 cells to block Fc receptors.
The cells were then stained with phycoerythrin-conjugated anti-CD4 (clone
RM4-5; Pharmingen, San Diego, Calif.) and fluorescein isothiocyanate-conju-
gated anti-CD8 (clone 53-6.7; Pharmingen) at a concentration of 1 mg/106 cells
for 25 min at 4°C. After being washed three times with ice-cold phosphate-
buffered saline containing 1% (vol/vol) FCS and 15 mM sodium azide, the cells
were analyzed with a FACScan flow cytometer (Becton Dickinson, San Jose,
Calif.). Dead cells were excluded on the basis of forward and side scatter, and
data analysis was performed on 20,000 acquired events with the computer pro-
gram Cicero (Cytomation, Fort Collins, Colo.).
RESULTS AND DISCUSSION
The CTL response of BALB/cJ mice to LCMV is dominated
by Ld-restricted, CD81 CTL (24). Furthermore, it has been
estimated that .95% of the CTL induced by LCMV infection
of BALB/c mice recognize the NP residue 118 to 126 peptide
bound to Ld (36). We examined whether KOD mice generated
Ld-restricted, NP-specific CTL following infection with
LCMV. As expected, spleen cells taken from BALB/cJ mice 8
days after i.p. infection with either 2 3 102 or 2 3 104 PFU of
LCMV had high levels of CTL activity against C1R-Ld/NP cells
(Fig. 1A). Surprisingly, we found that spleen cells from
LCMV-infected KOD mice, like spleen cells from BALB/cJ
mice, also killed C1R-Ld/NP cells (Fig. 1B). The control cell
lines C1R-Ld/p8901 and C1R-neo/NP were not killed by these
CTL, indicating that the LCMV-induced CTL activity in KOD
mice is both antigen specific and MHC restricted. We obtained
similar results using LCMV-infected and noninfected L cells
(H-2k) transfected with Ld as target cells (data not shown).
Like the BALB/cJ-derived CTL, the LCMV-specific CTL from
KOD mice recognized the immunodominant Ld-restricted NP
118 to 126 epitope. C1R-Ld cells that had been incubated with
NP 118 to 126 were killed efficiently by spleen cells from
LCMV-infected BALB/cJ mice (Fig. 1A) and by spleen cells
from LCMV-infected KOD mice (Fig. 1B). Thus, following
FIG. 1. KOD mice generate LCMV NP-specific, Ld-restricted CTL in response to virus infection. BALB/cJ mice (A) and KOD mice (B) were infected i.p. with 2 3
104 PFU of LCMV. Eight days later, spleen cells from these mice were tested for cytotoxic activity against a panel of cell lines by standard 51Cr-release assays. The
cell lines tested were C1R-neo (F), C1R-Ld/p8901 (■), C1R-neo/NP (E), and C1R-Ld/NP (h) and C1R-Ld (Œ) which was incubated with the NP residue 118 to 126
peptide prior to assay. Similar results were obtained following i.p. infection of mice with 2 3 102 PFU of LCMV. (C) AKR/J mice (broken lines) and AKR.b2m2 mice
(solid lines) were infected i.p. with 2 3 104 PFU of LCMV. Eight days following infection, spleen cells from these mice were tested for cytotoxic activity against L cells
(H-2k, ■ and h) or MC57 cells (H-2b, F and E) that were either infected with LCMV (■ and F) or mock infected (h and E). Representative results from four (A
and B) and three (C) independent experiments are shown.
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LCMV infection, KOD mice generated Ld-restricted, NP-spe-
cific CTL. We have previously reported that H-2b b2m
2 mice
do not generate MHC class I-restricted CTL following LCMV
infection (23). Furthermore, unlike AKR/J mice, AKR.b2m
2
mice (H-2k) do not generate MHC class I-restricted CTL fol-
lowing i.p. infection with LCMV (Fig. 1C). Thus, the ability of
b2m
2 mice to generate LCMV-specific, MHC class I-restricted
CTL following virus infection seems to be restricted to b2m
2
mice of the H-2d haplotype.
We performed in vitro complement depletion experiments
to determine the phenotype of the KOD CTL responsible for
the virus-specific, Ld-restricted cytotoxic activity. Treatment
of spleen cells from LCMV-infected KOD mice with anti-
bodies against CD4, followed by complement, had no effect on
the LCMV-specific, Ld-restricted CTL activity. In contrast,
treatment of these spleen cells with anti-CD8 followed by com-
plement totally removed the LCMV-specific, Ld-restricted cy-
totoxic activity (Fig. 2). These data indicate that the virus-specific,
Ld-restricted CTL response following LCMV infection of
KOD mice like the response of wild-type mice, is mediated by
CD42 CD81 T cells. We next examined the spleens of KOD
mice for evidence of expansion of CD81 T cells in response to
LCMV infection. Eight days after i.p. infection of control
BALB/cJ mice with 2 3 104 PFU of LCMV, there was an
approximately twofold increase in the percentage of splenic
CD81 cells (Fig. 3A and B). Less than 1% of the spleen cells
from noninfected KOD mice expressed CD8 (Fig. 3C); how-
ever, 8 days after LCMV infection of these mice there was
almost a fivefold increase in the percentage of splenic CD81
cells (Fig. 3D). Taken together with the CTL assay results,
these data indicate that LCMV infection of KOD mice results
in expansion of virus-specific, CD81, Ld-restricted CTL.
The CTL response of KOD mice to LCMV differs from that
observed in H-2b b2m
2 mice. We have previously reported that
H-2b b2m
2 mice generate CD41 MHC class II-restricted CTL
in response to LCMV infection (23, 27, 37). We were unable to
detect LCMV-specific, MHC class I-restricted T cells in these
mice even following in vitro restimulation of spleen cells or by
testing more than 300 T-cell hybridomas generated with
splenocytes from B6.b2m
2 mice (H-2b) which had been acutely
infected with LCMV (data not shown). Furthermore, an in-
crease in splenic CD81 cells in B6.b2m
2 mice following
LCMV infection was not detected (36a). These data are con-
FIG. 2. LCMV-specific Ld-restricted CTL in KOD mice are CD42 CD81.
Spleen cells were prepared from LCMV-infected KOD mice 8 days after i.p.
infection with 2 3 104 PFU of LCMV. Prior to use in CTL assays, spleen cells
were treated with complement only (■), anti-CD4 plus complement (‚), or
anti-CD8 plus complement (h) or were left untreated (Œ and F). Target cells
were C1R-Ld/NP (Œ, ■, ‚, and h) or C1R-neo/NP (F). The LCMV-specific
CTL activity in the spleens of LCMV-infected KOD mice is completely removed
by treatment with anti-CD8 plus complement. Depletion of CD41 cells has little
effect on the level of CTL activity. Representative results from one of three
independent experiments are shown.
FIG. 3. Expansion of CD81 cells following LCMV infection of KOD mice. BALB/cJ (A and B) and KOD (C and D) mice were either injected i.p. with 2 3 104
PFU of LCMV (B and D) or left untreated (A and C). Eight days later, spleen cells were prepared from these mice and were stained with phycoerythrin
(PE)-conjugated anti-CD4 and with fluorescein isothiocyanate (FITC)-conjugated anti-CD8. Compared with results with the noninfected mice, there was an expansion
of CD42 CD81 cells in both strains of mice following LCMV infection. Representative results from one of three independent experiments are shown.
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sistent with results of a previous study showing that spleens
from noninfected as well as from LCMV-infected H-2b b2m
2
mice contain less than 1% CD81 cells (8). Therefore, although
H-2b b2m
2 cells express MHC class I molecules, particularly
Db (1, 6), which can present endogenously derived antigen to
CD81 T cells from normal mice (14, 19, 26, 39), the level of
expression of MHC class I complexes in B6.b2m
2 mice is not
sufficient to elicit a CD81 T-cell response in vivo. Similarly, we
were also unable to detect LCMV-specific, MHC class I-re-
stricted CTL in AKR.b2m
2 mice (Fig. 1C). Thus, the Ld class
I molecule appears unique in its ability to function efficiently in
the absence of b2m. Our results are in agreement with the
findings of Cook et al. (9). Using a different strain of KOD
mice, those authors demonstrated the induction of antigen-
specific CD81 CTL following injection of Ld-binding peptides.
This result indicates that the level of Ld expression on the
surfaces of b2m
2 cells in vivo is sufficient to elicit a MHC class
I-restricted CTL response. Our data from infection with virus
rather than injection of peptides extend these observations.
The induction of virus-specific, Ld-restricted CD81 CTL fol-
lowing LCMV infection of KOD mice indicates that, in the
absence of b2m, the level of expression of endogenously de-
rived NP residues 118 to 126 in association with Ld is sufficient
to induce a CTL response in vivo. These data also indicate that,
at least for NP residues 118 to 126, b2m is not an absolute
requirement for the presentation of endogenous antigen in
association with Ld.
We next examined whether the virus-specific CD81 CTL in
KOD mice are functional in vivo. Following i.c. infection with
LCMV, normal mice succumb to aseptic meningitis and die 6
to 9 days following infection. This lethal disease is mediated by
LCMV-specific CD81 MHC class I-restricted CTL (21, 22). i.c.
infection of KOD mice with either 2 3 103 or 2 3 105 PFU of
LCMV resulted in death of 8 of 10 and 6 of 8 animals, respec-
tively, 7 to 9 days after i.c. infection (Fig. 4). The symptoms of
LCM disease in KOD mice were similar to those observed in
i.c. infected BALB/cJ mice. In vivo depletion of CD81 cells
prior to i.c. infection prevented lethal LCM disease in KOD
mice, whereas depletion of CD41 cells had no effect on disease
(Fig. 4). Thus, the disease observed following i.c. infection of
KOD mice with LCMV is similar to that seen in i.c. infected
wild-type mice. Furthermore, the observation that KOD mice
succumb to CD81 T-cell-dependent lethal LCM disease sug-
gests that the virus-specific CD81 CTL from these mice that
we detected in vitro are functional in vivo. Since clearance of
LCMV is also dependent on CD81 CTL (20, 37), we examined
whether KOD mice could control LCMV infection. As shown
in Table 1, KOD mice which were infected i.p. with 2 3 104
PFU of LCMV contained high levels of virus in their spleens
20 days and 120 days after infection. Moreover, by day 20
following i.p. infection with 2 3 102 PFU of LCMV, the virus
had disseminated and was detectable in the spleen, liver, and
brain (Table 2). Interestingly, none of the strains of b2m
2 mice
that we examined were capable of clearing LCMV infection
(Table 1). This result is not surprising for B6.b2m
2 mice and
AKR.b2m
2 mice, which lack detectable MHC class I-restricted
CTL activity following LCMV infection. In contrast, infection
of KOD mice with 2 3 102 or 2 3 104 PFU of LCMV resulted
in high levels of virus-specific, MHC class I-restricted CTL
activity, yet these mice also failed to eliminate LCMV. The
inability of the virus-specific Ld-restricted CTL in KOD mice
to clear LCMV infection is puzzling. The failure of KOD mice
to clear LCMV contrasts with the antiviral response observed
in BALB/c-H-2dm2 mice. BALB/c-H-2dm2 mice lack Ld and
generate low levels of LCMV-specific CTL activity following
infection. Unlike KOD mice, BALB/c-H-2dm2 mice clear
LCMV infection (13). In addition, the low levels of virus-
specific, MHC class I-restricted CTL detectable in CD8-defi-
cient mice (5) are also sufficient to clear LCMV infection (12).
Because MHC class I-restricted CTL activity is readily detect-
able in LCMV-infected KOD mice, unlike in BALB/c-H-2dm2
and CD8-deficient mice, it is unlikely that the inability of KOD
mice to control LCMV infection is due to insufficient numbers
of MHC class I-restricted CTL. An alternative possibility is
that in KOD mice, LCMV persists in cells that do not express
sufficient levels of Ld to be recognized and killed by virus-
FIG. 4. Lethal LCM disease in KOD mice is dependent on CD81 cells.
BALB/cJ (a) (n 5 4) and KOD (b to f) mice were injected i.c. with either 2 3 103
PFU (a to d) or 2 3 105 PFU (e) of LCMV or with an equivalent volume of
phosphate-buffered saline (f) (n 5 5). Prior to infection, selected groups of KOD
mice were depleted of CD81 (c) (n 5 8) or CD41 (d) (n 5 5) cells by injection
of specific antibody (27). Mice were monitored daily for morbidity and mortality.
In the experiment whose results are shown, 8 of 10 (b) and 6 of 8 (e) nonde-
pleted, KOD mice died following i.c. infection with 2 3 103 and 2 3 105 PFU of
LCMV, respectively.
TABLE 1. KOD mice do not clear LCMV
Mouse strain Days after infectiona
Log10 PFU/g of tissueb
Expt 1 Expt 2
KOD Noninfected ,3 ,3
BALB/cJ 20 ,3 ,3
120 ,3 ,3
KOD 20 6.90 7.10
120 7.00 6.95
AKR.b2m
2 120 7.16 7.23
B6.b2m
2 120 7.23 7.00
a Mice were infected i.p. with 2 3 104 PFU of LCMV in a volume of 0.4 ml.
b Values are the levels of virus detected in the spleens of individual mice. The
limit of detection of the assay is 3 log10 PFU/g.
TABLE 2. Dissemination of virus in LCMV-infected KOD mice
Mouse strain Days after infectiona
Log10 PFU/g of tissue inb:
Spleen Liver Brain
KOD Noninfected ,3 ,3 ,3
BALB/cJ 20 ,3 ,3 ,3
20 ,3 ,3 ,3
KOD 20 7.0 6.6 4.4
20 7.2 7.2 6.1
20 7.8 8.0 5.6
a Mice were infected i.p. with 2 3 102 PFU of LCMV in a volume of 0.4 ml.
b Values are the levels of virus detected in tissues of individual mice 20 days
following i.p. infection with LCMV. The limit of detection of the assay is 3 log10
PFU/g.
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specific CTL. This possibility is consistent with the observation
that the level of expression of MHC class I on b2m
2 fibroblasts
is substantially lower than that on b2m
2 T cells (25a). LCMV-
infected cells that express insufficient levels of Ld for CTL
recognition may, therefore, act as a reservoir of virus in vivo.
In conclusion, we have demonstrated that KOD mice gen-
erate NP-specific, CD81, Ld-restricted CTL following virus
infection. This is the first report of MHC class I-restricted,
CD81 CTL induction in b2m
2 mice in response to virus in-
fection. The ability of KOD mice to generate CD81, Ld-re-
stricted CTL indicates that b2m expression is not an absolute
requirement for the presentation of endogenous peptide anti-
gen in association with Ld.
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